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Abstract
Background: Despite the clear harm associated with smoking tobacco, many people with smoking-related
chronic diseases or serious mental illnesses (SMI) are unwilling or unable to stop smoking. In many cases,
these smokers have tried and exhausted all methods to stop smoking and yet clinicians are repeatedly
mandated to offer them during routine consultations. Providing nicotine through electronic cigarettes (e-
cigarettes) may reduce the adverse health consequences associated with tobacco smoking, but these are not
currently offered. The aim of this study is to examine the feasibility, acceptability and effectiveness of general
practitioners (GPs) and nurses delivering a brief advice intervention on e-cigarettes and offering an e-cigarette
starter pack and patient support resources compared with standard care in smokers with smoking-related
chronic diseases or SMI who are unwilling to stop smoking.
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Methods/design: This is an individually randomised, blinded, two-arm trial. Smokers with a smoking-related chronic
condition or SMI with no intention of stopping smoking will be recruited through primary care registers. Eligible participants
will be randomised to one of two groups if they decline standard care for stopping smoking: a control group who will
receive no additional support beyond standard care; or an intervention group who will receive GP or nurse-led brief advice
about e-cigarettes, an e-cigarette starter pack with accompanying practical support booklet, and telephone support from
experienced vapers and online video tutorials. The primary outcome measures will be smoking reduction, measured
through changes in cigarettes per day and 7-day point-prevalence abstinence at 2 months. Secondary outcomes include
smoking reduction, 7-day point-prevalence abstinence and prolonged abstinence at 8 months. Other outcomes include
patient recruitment and follow-up, patient uptake and use of e-cigarettes, nicotine intake, contamination of randomisation
and practitioner adherence to the delivery of the intervention. Qualitative interviews will be conducted in a subsample of
practitioners, patients and the vape team to garner their reactions to the programme.
Discussion: This is the first randomised controlled trial to investigate whether e-cigarette provision alongside a brief
intervention delivered by practitioners leads to reduced smoking and abstinence among smokers with smoking-related
chronic diseases or SMI.
Trial registration: ISRCTN registry, ISRCTN59404712. Registered 28/11/17.
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Background
Although smoking has more than halved since the
1970s, 14.7% of adults in the UK still smoke [1], costing
the National Health Service (NHS) £2.5 billion a year
from treating smoking-related chronic diseases [2]. Re-
ducing smoking remains a key public health priority,
particularly among those with smoking-related chronic
diseases and serious mental illnesses (SMI), as their
health can improve if they stop smoking or decline if
they continue. In people with chronic obstructive pul-
monary disease (COPD) continued smoking increases
the risk of hospitalisation and chest infections and stop-
ping smoking is the only intervention known to decrease
the rate of decline in lung function [3, 4]. In hyperten-
sion, diabetes and chronic kidney disease, continued
smoking leads to more rapid progression of renal disease
[5–7]. In asthma, smoking cessation improves symptom
control and can decrease the need for medication [8, 9].
In ischaemic heart disease, smoking cessation reduces
recurrence by a third, more than any other therapeutic
intervention [10]. Stopping smoking is associated with
reduced anxiety and stress among people with mental
health conditions [11]. Overall, quitting reduces mortal-
ity, even in people with smoking-related morbidity [12,
13]. Although almost everyone with a serious smoking-
related disease tries to stop smoking on diagnosis [14],
relapse is common, with evidence that most smokers
continue smoking [15].
People with smoking-related conditions are often
called ‘hardcore smokers’ because they have often tried
and failed to stop smoking, despite trying most available
means [16]. Similarly, smokers with SMI are often de-
fined as hardcore smokers as they tend to smoke more
heavily and find it more difficult to quit than those with-
out SMI [17]. Primary care practitioners are well-placed
to support these groups in stopping smoking and this is
encouraged in general practices in the UK through a
‘pay for performance’ contract called the Quality and
Outcomes Framework (QOF) [18]. The QOF rewards
GPs for providing quality care for people with smoking-
related illnesses and SMI. Since inception, GPs have
had to offer advice on smoking, and since 2012, they
offer referral for support and pharmacotherapy annu-
ally to people with smoking-related conditions and
with serious mental health disorders. While the QOF
has improved rates of recording advice and referrals
[19], some smokers are still less likely to receive help
in quitting [20].
There are several reasons why people continue to
smoke despite sincere desire not to do so. Tobacco ad-
diction is driven by several factors including social, psy-
chological and environmental influences, but it is the
physiological effect of nicotine that underpins smoking
behaviour [21]. Nicotine is positively reinforcing through
the release of the chemical dopamine in the brain, which
produces feelings of pleasure. The rewarding effects of
nicotine start to dissipate within hours of the last
cigarette smoked, after which smokers experience dis-
comfort in the form of withdrawal symptoms and urges
to smoke [22]. Smoking alleviates nicotine withdrawal
and so a cycle of continued smoking ensues to amelior-
ate these symptoms and maintain nicotine levels. With
repeated cigarette use, smokers come to associate par-
ticular moods, environmental cues or the sensory as-
pects of smoking with the rewarding effects of nicotine
until these smoking-related cues are sufficient to
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instigate urges to smoke and maintain smoking behav-
iour in their own right [23].
While people smoke for their need for nicotine, it is
the other constituents in tobacco smoke that cause al-
most all harm [24]. The adverse health consequences of
continuing to smoke can largely be avoided if smokers
obtain nicotine through less harmful sources than smok-
ing cigarettes. While licensed nicotine replacement ther-
apy (NRT) offers this, electronic cigarettes, known as e-
cigarettes, have become the most popular non-tobacco
system for obtaining nicotine. Around 32% of smokers
are using e-cigarettes to support quit attempts, which is
substantially more than those who are using prescription
medication (4%), purchasing NRT over the counter
(14%) or using NHS Stop Smoking Services (1%) [25,
26]. Of those who smoke and use nicotine from other
sources, around 19% use e-cigarettes compared with 7%
using NRT [26]. The National Centre for Smoking Ces-
sation Training (NCSCT) recommends that stop smok-
ing practitioners “be open to electronic cigarette use in
people keen to try them; especially in those that have
tried, but not succeeded, in stopping smoking with the
use of licensed stop smoking medicines” [27]. The evi-
dence suggests that e-cigarettes appeal particularly to
people who do not want to stop smoking [28]; however,
primary care services are unable to prescribe them, as
there is no medically licensed e-cigarette currently avail-
able in the UK.
While research on the safety and efficacy of e-
cigarettes is ongoing, sufficient evidence indicates that
they are substantially less harmful than combustible to-
bacco [29–32], making them particularly suitable for
harm reduction [28, 33]. Studies of e-cigarette use in
smokers with no intention of quitting have shown prom-
ising findings, suggesting they promote reduction and
cessation [34–36]. E-cigarettes could appeal because they
appear to be about switching not quitting, and thereafter
allow people to cut down and eventually stop smoking
when they find that the e-cigarette meets their needs.
There is strong trial evidence that NRT helps smokers
with no immediate intention to quit to reduce and quit
in this way [37, 38]. Recent estimates in 2018 suggest
that e-cigarettes could be contributing to an additional
22,000–57,000 quitters in England who would not have
stopped otherwise [39].
A Cochrane review on e-cigarettes for cessation
showed that approximately 9% of smokers who used e-
cigarettes were able to stop smoking at up to one year
compared with 4% of smokers who used nicotine-free e-
cigarettes [39]. In those who did not quit, 36% of e-
cigarette users halved the number of conventional ciga-
rettes they smoked compared with 27% of users on pla-
cebo. Furthermore, none of the studies found that
smokers who used e-cigarettes for two years or less had
an increased health risk compared with smokers who
did not use e-cigarettes. Since the Cochrane review, a
large randomised controlled trial comparing e-cigarettes
with NRT alongside behavioural support found an al-
most two-fold increase in quitters at one year in the e-
cigarette group [40]. Another randomised controlled
trial found that among smokers who did not want to
quit, 34% of those given an e-cigarette quit smoking
compared with 0% of those not given an e-cigarette. The
group given e-cigarettes also reduced their cigarette con-
sumption substantially more than those who were not
given e-cigarettes [41]. While some population studies
have detected similar effects on cessation [42, 43] and
not all observational studies have done so [44], it is clear
that more clinical studies are needed, particularly in
smokers who have no intention of quitting.
Several UK health authorities including the National
Institute for Health and Care Excellence (NICE), Public
Health England and the Royal College of Physicians have
stated that primary care physicians should offer advice
to smokers about using e-cigarettes as a means to stop-
ping smoking [24, 45, 46]. We know that many physi-
cians are being asked about e-cigarettes by their patients
and some are recommending their use [47], but little is
known about the type of information that is being com-
municated and the impact this has on patients’ use.
Health professionals appear to be uninformed [48];
smoking cessation practitioners have expressed confu-
sion about e-cigarettes and a desire to provide better in-
formation to service users, although brief training can
improve knowledge and confidence [49]. If smoking ces-
sation specialists are confused, it is likely that primary
care doctors and nurses will be even less aware, drawing
their knowledge from stories in the media, many of
which feature alarmist and misleading information on
the risks of e-cigarettes [45, 50]. Training practitioners
on e-cigarettes and their use as a harm reduction ap-
proach is therefore important and is addressed in this
study.
GP brief interventions on smoking motivate more
people to take action when GPs offer help to change ra-
ther than advice to do so on medical grounds [51]. Fur-
thermore, there is evidence that providing immediate
connection to help rather than leaving the patient to
seek it leads to a ten-fold increase in the rate of use of
help [52]. GP brief advice is a potent prompt to change
patients’ behaviour, which has been found in a trial of a
30-sec GP brief intervention for weight loss [53]. The
study team screened for obesity and asked anyone who
was willing to join the trial and 83% agreed. In the active
intervention, the GP offered help to lose weight and
an immediate booking for support. Overall, 77% of over-
weight patients agreed to a referral to a weight manage-
ment service and 44% attended. A similar approach will
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be used here, where GPs and nurses will give brief ad-
vice and offer an e-cigarette to hardcore smokers (i.e.
those unwilling to quit), with smoking-related chronic
diseases or SMI. The theory underpinning this approach
comes from Social Cognitive Theory to build on patient
and practitioner motivation, skills, positive outcome ex-
pectations and self-efficacy [54].
The aim of this study is to examine the feasibility, ac-
ceptability and effectiveness of an intervention to en-
courage hardcore smokers with smoking-related chronic
diseases or SMI who are unwilling to quit to switch to e-
cigarettes and investigate how this might affect their
smoking behaviour compared with standard care. The
intervention comprises a brief behavioural intervention
by a GP or practice nurse to promote the use of e-
cigarettes, providing an e-cigarette starter pack, a prac-
tical support booklet, online tutorials and ongoing tech-




The primary objective is to examine the effectiveness of
a brief GP/nurse behavioural intervention to encourage
switching to e-cigarettes, provision of e-cigarettes and
ongoing technical support from experienced e-cigarette
users in producing short-term reductions in cigarette in-
take and smoking abstinence.
Secondary objectives
The secondary objectives are: to examine recruitment and
follow-up of patients; to examine smokers’ uptake and use
of offered e-cigarettes; to assess contamination of random-
isation; to examine nicotine intake; to assess the adherence
of primary care teams in delivering brief interventions; to
examine practitioners’ reactions towards offering e-
cigarettes and experiences of delivering the intervention; to
examine patients’ reactions to the programme; to examine
the vape team’s reactions towards supporting patients in
their use of e-cigarettes; and to examine the effectiveness of
a GP/nurse-led brief intervention for smoking on long-
term reductions in cigarette intake and smoking abstinence.
For more information on the objectives, outcomes and
time-points of measures, see Additional file 1.
Methods/design
Study design
This is a two-centre, individually randomised, two-arm,
parallel group study. The study will take place in general
practices in England. Smokers with a smoking-related
chronic disease or SMI and who have no intention of stop-
ping immediately or seeking cessation support will be ran-
domised to one of two groups, if they decline referral to
NHS stop smoking services (SSS) and smoking cessation
medication: an intervention group offered encouragement
by their practitioner to use an e-cigarette, or a standard care
control group who will receive nothing beyond the usual
care already provided prior to randomisation. Participants
in the intervention group will be offered an e-cigarette
starter pack and accompanying practical support booklet;
this will contain details for a telephone call back service run
by experienced vapers for technical support and a website
with an online video tutorial. Patients will attend four visits
at their GP practice: a baseline visit, a therapeutic visit with
their GP or nurse and two follow-up visits 2 months and 8
months post-consultation.
Participant entry
A total of 320 participants will be recruited into the trial:
160 participants in each of the two treatment arms. See
Fig. 1 for the planned flow of participants through the
trial and Additional file 2 for the SPIRIT checklist.
Recruitment
Recruitment centres at the Universities of Oxford and Not-
tingham (United Kingdom) will recruit through GP prac-
tices. General practice teams review patients with chronic
diseases at least annually, which includes enquiry about
smoking status and, for smokers, offer of help to quit smok-
ing. Around 20–30 GP practices will search their patient
databases for all current smokers with one or more chronic
conditions who are due to have an annual review in the
new QOF year, beginning in April 2018. GPs will screen
the search list to ensure that all those identified are medic-
ally appropriate to participate in the trial. Practice staff will
write to or send a text message to these patients inviting
them to take part. Patients who are interested in taking part
will contact the study team by telephone, text message,
email or return reply slip.
The study team will carry out preliminary screening
and if the patient appears to be eligible, s/he will be
asked to attend a baseline assessment at their GP prac-
tice to confirm eligibility (see Additional file 3 for enrol-
ment process). A participant information sheet (PIS; see
Additional file 4) and baseline appointment confirmation
letter will be sent to potential participants.
Inclusion criteria
 Participant is willing and able to give informed
consent for participation in the study
 Aged 18 years or above
 Current smoker with a value of at least 10 parts per
million (ppm) for exhaled carbon monoxide (CO) and
smokes a minimum of eight cigarettes/8 g of tobacco
per day (including pipe, cigars or tobacco roll-ups)
 Diagnosed with one or more of the following
chronic conditions: ischaemic heart disease,
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peripheral vascular disease, hypertension, diabetes
mellitus (type 1 and type 2), stroke, asthma, COPD,
chronic kidney disease, depression, schizophrenia,
bipolar disorder or other psychoses
Exclusion criteria
 GP believes that switching to e-cigarettes would not
benefit the patient given their current medical
condition
 Currently using e-cigarettes, nicotine replacement
therapy or other cessation therapies (e.g. bupropion,
nortriptyline or varenicline)
 Plans to stop smoking before or at the annual review
 Currently enrolled in another smoking-related study
or other study where the aims of the studies are
incompatible
 Cannot consent due to mental incapacity
 Pregnant, breastfeeding or planning to become
pregnant during the course of the study
Withdrawal criteria
Each participant has the right to withdraw from the trial
at any time. The PIS will provide details on how to with-
draw and who to contact should the participant no lon-
ger wish to participate in the trial. If the participant
Fig. 1 Planned participant flow through the trial
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wishes to withdraw we will use their data up to the point
that they withdrew unless they request that we do not
do so. Such patients will not be replaced. There are no
withdrawal criteria other than the participant or practi-
tioner’s request to withdraw, which will be dealt with on
a case by case basis.
Failure to attend follow-up visits will not count as
withdrawal from the trial; patients will be classed as
smokers and as not having reduced consumption.
Randomisation and blinding
Participants will be randomised to intervention or con-
trol with a 1:1 allocation ratio. A randomisation list will
be generated by the trial statistician using the current
version of Stata and validated by a second statistician
within the Primary Care Clinical Trials Unit (PC-CTU).
The randomisation will be stratified by practice and will
use varying block sizes to ensure allocation concealment.
The randomisation list will then be passed to someone
independent of the trial who will create the randomisa-
tion envelopes.
Practitioners will randomise patients during the annual
review appointment. On the day of the annual review
session, a researcher will give each practitioner a set of
opaque A5 sealed envelopes, which will contain a
colour-coded randomisation card. The envelopes will be
numbered in sequence. The GP or practice nurse will
only open the randomisation envelope after they have
delivered usual care advice on smoking and are satisfied
that the patient meets eligibility for the trial, i.e. the pa-
tient confirms that s/he is currently a smoker and de-
clines usual care treatment for stopping smoking. The
patient is classed as enrolled in the trial only after the
randomisation envelope has been opened. The random-
isation card inside the sealed envelope will reveal the pa-
tient’s treatment allocation to the GP or nurse, but not
the patient. The randomisation envelope will be returned
to the researcher by the patient after their consultation.
If the patient is no longer a smoker or accepts usual
care treatment, practitioners will fill in a patient ineligi-
bility card containing a tick box option to select if they
did not randomise and enrol the patient into the trial.
The tick box will indicate the reason for non-enrolment,
i.e. patient has stopped smoking, patient accepted usual
care or any other reason where it is deemed clinically in-
appropriate. The ineligibility card will be returned to the
researcher after the session and the patient will be
thanked for their time given to the study and debriefed.
Due to the nature of the trial, GPs and practice nurses
will be aware of the patient’s treatment allocation to en-
sure that the correct intervention is given. Therefore,
practitioners who are delivering the intervention cannot
be blinded to treatment. While patients will know
whether they have been offered support to cut down by
using an e-cigarette or not by their GP or nurse, the pa-
tient will not be informed that this study is investigating
this specifically and therefore will in some respects re-
main blind to allocation. All patient-facing materials will
therefore refer to the study’s short title, ‘Management of
Smoking in Primary Care’ (MaSC), so that the nature of
the trial remains concealed.
Study visits
Figure 2 provides a summary of participant activities and
assessments by study visits.
Baseline visit
The baseline visit will take place in the patient’s GP
practice. The researcher will assess the patient’s eligibil-
ity and obtain written informed consent (Add-
itional file 5). The researcher will check for eligibility
based on the patient’s medical history, medication use,
current e-cigarette use and smoking status, which will
be biochemically verified through exhaled carbon mon-
oxide (CO) readings. Medical history and medication
use may be checked against the participant’s primary
care records to ensure accuracy and completeness. The
researcher will also collect basic demographic data, in-
formation on smoking history and a saliva sample.
Table 1 outlines the data that will be collected at
baseline.
Therapeutic visit
Participants will be invited to attend an annual review
appointment for their chronic condition in the new
QOF year, from April 2018. The intervention will be de-
livered by the GP or practice nurse during this
appointment.
A researcher will be present in the GP practice on the
day of the participant’s annual review appointment to re-
mind practitioners of the study procedures and to collect
data after the consultation. Neither clinicians nor pa-
tients are reliable reporters of their communication be-
haviour [55] and recording does not seem to change
consultation content or behaviour [56]. Therefore, audio
recordings will be used to monitor adherence to the
intervention (including quality of delivery as well as im-
mediate patient responsiveness) and the degree of local
tailoring being adopted across practitioners and prac-
tices. The recordings will be checked by the study team
using a study-specific behaviour checklist.
During the consultation, the practitioner will enquire
about the participant’s smoking status. If the participant
reports that they no longer smoke, the practitioner will
complete a patient ineligibility card and cease to provide
any further smoking cessation advice. If the participant
confirms that they are a smoker, the practitioner will de-
liver usual care as outlined below. The GP/practice
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nurse will open a randomisation envelope if the partici-
pant is eligible for the trial, i.e. the participant declines
usual care treatment. Participants randomised to the
control group will be given no further advice beyond
what they have been given (i.e. offered usual care), while
the intervention group will be offered an e-cigarette
starter pack and support materials. At the end of the
consultation, all participants will be asked to return the
randomisation card and envelope to a researcher who
will be waiting in another room. The researcher will
then ask the participant to complete a post-consultation
questionnaire to assess the quality of advice given during
their consultation and contamination, via recall of key
points of the consultation. The consultation audio-
recording will be reviewed if the post-consultation ques-
tionnaire reveals that contamination has occurred, i.e.
participants in the control group recall that e-cigarettes
were mentioned by the GP/nurse. If the recording con-
firms contamination, the researcher will deliver brief re-
fresher training to the practitioners concerned.
Fig. 2 Schedule of study visits, procedures and assessments
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Two-month follow-up
Study staff will contact participants and schedule a
follow-up appointment at the GP practice or carry out a
home visit 2 months after randomisation. At this visit,
the researcher will record information on the types of
medication currently used, and any adverse events. S/he
will collect information on smoking behaviour including
self-reported smoking status, the number of cigarettes
smoked per day, current pack/pouch size, use of e-
cigarettes and pharmacotherapy (NRT, varenicline or
bupropion) and nicotine dependence. A saliva sample
and exhaled CO measurement will be taken by the re-
searcher. S/he will also record whether the participant
accessed any type of support (e.g. NHS SSS) for stopping
or reducing smoking since randomisation. If the partici-
pant reports that they have stopped smoking and they
are taking a particular medication that requires a dose
adjustment due to this, the participant’s GP will be in-
formed. For intervention group participants, we will as-
sess the frequency of telephone support and use of the
online video tutorial. If participants are unable to attend
a practice visit or a home visit, information on smoking
behaviour will be collected by telephone, text message or
email. Salivettes will be posted out to participants with
instructions on how to give a saliva sample and a pre-
paid envelope will be provided for returning the sample
back to the study team.
Eight-month follow-up
The study team will contact all participants 6 months
after their 2-month follow-up by telephone, text message
or email to establish smoking status, number of ciga-
rettes smoked per day, current pack/pouch size, use of
pharmacotherapy, use of e-cigarettes and any serious ad-
verse events (SAEs). Participants who declare abstinence
will be invited to return to the practice or receive a
home visit by a member of the study team for exhaled
CO measurement to confirm this. Every effort will be
made to contact participants exactly 6 months after the
2-month follow-up, before data are classed as lost to
follow-up. If the participant is unable to provide a CO
measurement to validate abstinence, a salivette will be
posted to the participant with instructions on how to re-
turn the sample back to the study team. Again, if the
participant reports that they have stopped smoking and
they are taking a particular medication that requires a
dose adjustment, the participant’s GP will be informed.
Treatments
Treatment arms
Control Practitioners will deliver routine smoking cessa-
tion advice and treatment to all patients. Although usual
care varies by practice, this typically involves standard
brief advice about stopping smoking and assistance to
do so either by referral to the NHS SSS or offer of
pharmacotherapy. Some practices offer in-house SSS de-
livered by nurses or healthcare assistants trained to pro-
vide stop smoking support. In some practices,
practitioners prescribe cessation medication. Pharmaco-
therapies provided as part of this support by the practi-
tioner or through the SSS referral include either nicotine
replacement therapy (used as single form or combin-
ation NRT), varenicline or bupropion. If the patient
agrees to a referral to the SSS or accepts a prescription
for pharmacotherapy, the GP/practice nurse will fill in a
patient ineligibility card. Practitioners will only open the
randomisation envelope if the patient declines usual care
treatment. If the randomisation card reveals that the pa-
tient is allocated to the control arm, no further action
will be necessary as the GP/practice nurse has delivered
all components of usual care.
Intervention Participants in the intervention group will
have already received usual care by the GP or practice
nurse as described above for the control group. If rando-
mised to the intervention group, the GP or practice
nurse will deliver brief advice about e-cigarettes. All
practitioners will receive online training in how to de-
liver the advice and motivate patients to take up the
offer of an e-cigarette. The GP/practice nurse will be en-
couraged to do the following during advice giving: de-
scribe the offer positively, establish the evidence-base for
e-cigarettes, emphasise switching from smoking and alle-
viate any health concerns about the risks of vaping. Each
practitioner will be given a prompt sheet as a reminder.
The GP/practice nurse will ask the participant whether
s/he would be willing to try an e-cigarette, upon which
the participant will be given an e-cigarette starter pack
and an accompanying practical support booklet. The
starter pack will contain three different flavoured bottles
of e-liquid in two nicotine strengths (2 × 18mg/ml and
1 × 12 mg/ml). Participants will need to purchase their
own e-liquid thereafter. They will also receive an
Table 1 Data collection at baseline visit
Demographics Basic demographic information
Medical history Medical problems and concomitant medication
Smoking history Information on smoking and quitting history
(age when started smoking, number of
cigarettes smoked per day, when the last
cigarette was smoked, type of cigarettes
smoked per day (roll-ups or factory-made),
usual pack/pouch size, nicotine dependence,
motivation to stop smoking, self-efficacy and
outcome expectancies, history of any
pharmacotherapy or e-cigarette use and
exhaled CO measurement)
Biological samples Saliva samples to measure anabasine
(for smoke intake) and cotinine (for nicotine intake)
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introductory call from an experienced vaper who will
help with any technical queries they might have when
first using the device. They will have the option to opt
out of receiving this call.
At the end of the consultation, practitioners will rec-
ord whether brief advice about e-cigarettes was given
and whether the e-cigarette starter pack was accepted.
Practical support booklet, telephone support service
and online tutorials Intervention group participants
will have access to three resources to promote patient
self-efficacy, skills and positive outcome expectations
about e-cigarettes, should they accept the offer of a
starter pack. The first resource is a practical support
booklet and will include the following: information on
what is an e-cigarette, instructions on how to set up the
device, how to refill and charge it, correct ways to vape,
a list of local shops that sell e-liquids and common is-
sues with use. The booklet will contain motivational
support to reinforce practitioners’ advice about e-
cigarettes, including the benefits of cutting down on cig-
arettes through e-cigarette use and addressing perceived
risks and concerns about first use.
The second resource available to participants is tele-
phone support. The practical support booklet will in-
clude the contact details of a dedicated team of
experienced vapers who will operate the telephone sup-
port service. Although the vape team will have specialist
knowledge on e-cigarette use, they will be trained in the
study procedures and protocol for delivering technical
support on e-cigarettes by staff at the University of Ox-
ford. Each member of the vape team will be assigned
10–15 participants to assist. The study team will identify
which participants accepted an e-cigarette starter pack,
after the annual review appointment. If the participant
accepted, his/her contact details will be passed on to a
member of the vape team. The vape team will contact
each participant to introduce themselves and offer any
assistance on the set up and use of the e-cigarette device
within one week of randomisation. Subsequently, partici-
pants will be able to contact the vape team through a
telephone support service; they can leave a message for
the vape team, who will return the call if they are unable
to take the call immediately. All calls will be audio-
recorded via a call-recording app on the study mobile
phone with the consent of participants to monitor the
advice provided by the vape team.
The practical support booklet will also include details
of a study-dedicated website featuring a series of online
video tutorials. The videos will include instructions on
how to use the e-cigarette, demonstrations with a non-
vaper and a testimonial from a vaper that switched from
smoking to e-cigarettes.
Practitioner training
The training will build on practitioner motivation, skills,
self-efficacy and positive outcome expectancies for en-
couraging adherence to the protocol and delivery of the
intervention [54]. LifeGuide, an open source software
platform, will be used to develop and deliver the training
online [57]. LifeGuide will allow us to control all aspects
of the design, making changes where necessary during
development and allow us to evaluate the usability and
acceptability of the training.
We will draw on quantitative research to collate the
evidence-base on the use of e-cigarettes for harm reduc-
tion, its use as a cessation aid and its safety profile to
form part of the educational component of the training.
This information—derived from sources such as the sys-
tematic review on e-cigarettes for reduction and cessa-
tion [39] and the Public Health England (PHE) evidence
update [50]—will be used to develop a set of ‘key facts’
on the benefits of cutting down in smokers with chronic
diseases. We will address practitioners’ main concerns
about e-cigarettes, which have been reported elsewhere
[48]. We will also draw on existing training resources of-
fered to stop smoking practitioners from the National
Centre for Smoking Cessation Training website. We will
convey what is known and unknown about e-cigarettes
and their place in treating smokers with no desire to
quit. This will be followed by training to use a few key
evidence-based behavioural methods from the behaviour
change technique (BCT) taxonomy [58] (e.g. problem
solving, instruction on how to perform a behaviour, ver-
bal persuasion to boost self-efficacy) that practitioners
will use to motivate hardcore smokers in the interven-
tion group to try e-cigarettes if they decline help to stop
smoking. This section will include video role-play sce-
narios between GPs and actors to show the skills in ac-
tion in different settings. We will explain how important
it is to trial integrity not to contaminate the study by of-
fering e-cigarettes and advice to the control group. The
training will outline the difference between what consti-
tutes the standard care for the control group and the
procedure to follow in the intervention group.
Practitioners will be given login details to access the
training before the start of the intervention period. The
study team will check that the training has been carried
out and completed prior to delivery. If there is any un-
certainty about the content and procedure, practitioners
will be able to contact the study team for clarification.
Embedded qualitative study
Participants in the intervention group will be asked
whether they would be willing to participate in a tele-
phone interview after the 2-month follow-up visit. We
will purposively select up to 40 participants who took up
the offer and tried an e-cigarette, those who reduced
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and/or quit and those who refused to use them. A semi-
structured interview guide will be used to assess patients’
knowledge of e-cigarettes, their experiences of use and
the degree to which the information provided by their
practitioner made a difference to them and their smok-
ing behaviour. Additionally, we will explore patients’
views on acceptability and appropriateness of being
given advice and an offer of an e-cigarette by their
practitioner.
We will conduct telephone interviews with up to 20
practitioners after they have seen their last enrolled pa-
tient to assess what worked well, any challenges faced
when delivering the intervention and the appropriate-
ness of the training received. We will also approach
members of the vape team after they have completed
their involvement in the study on what worked well and
any challenges faced in providing technical support to
participants in the trial. All interviews with patients,




The first primary outcome is 7-day point-prevalence ab-
stinence from smoked tobacco at 2 months. Abstinence
is defined as complete self-reported abstinence from
smoking—not even a puff—in the past 7 days, accom-
panied by a salivary anabasine concentration of < 1 ng/
ml. If there are technical issues with the analysis of saliva
samples (e.g. if there is not enough saliva present in the
sample for anabasine analysis), we will use exhaled CO
as verification of abstinence (CO < 10 ppm).
The second primary outcome is reduction in cigarette
consumption at 2 months. Reduction is defined as a 50%
reduction in self-reported cigarettes per day on each of
the last 7 days at 2 months compared with baseline con-
sumption, accompanied by evidence of reduced smoke
intake indicated by salivary anabasine concentrations
lower than baseline.
Secondary outcomes
Secondary outcome measures for abstinence include 7-
day point prevalence abstinence measured at 8 months,
biochemically confirmed by an exhaled CO of < 10 ppm.
We will also measure 6-month prolonged abstinence
using the Russell standard criteria, defined as smoking
fewer than five cigarettes between 2- and 8-month
follow-ups, confirmed by an anabasine concentration of
< 1 ng/ml at 2 months and an exhaled CO concentration
of < 10 ppm at 8 months (or anabasine concentration of
< 1 ng/ml at 8 months if CO measurement unavailable).
There is no funding for analysing all saliva samples at 8
months; therefore, we will verify abstinence using ex-
haled CO in the first instance.
As an additional measure of smoking reduction, we
will assess the mean change in salivary anabasine con-
centrations from baseline to 2 months.
Other measures and exploratory outcomes
Baseline assessments are detailed in Table 1. Ethnic
group will be classified using UK census 2015 categories.
The researcher will collect a saliva sample and measure
exhaled CO using a CO monitor as a measure of smoke
intake. Severity of nicotine dependence will be measured
using the six-item Fagerstrom Test for Cigarette De-
pendence (FTCD). The FTCD will be re-administered at
2- and 8-month follow-ups. We will assess motivation to
stop smoking with the question “How likely are you to
quit smoking within the next six months?” Responses
will be measured on a five-point Likert scale from “Very
unlikely” to “Very likely”.
Recruitment and follow-up outcomes will be measured
by recording the number of people in the population of
interest who respond to letters of invitation from the
practices, the number of people who consent to enrol-
ment into the study at baseline and the number of
people who complete follow-up at 2 and 8 months after
receiving the brief advice intervention.
GPs or nurses will record on the randomisation card
whether an e-cigarette starter pack was accepted or de-
clined by participants; this will be returned to the re-
searcher after the consultation. Use of e-cigarettes will
be assessed in a questionnaire administered at 2- and 8-
month follow-ups. Questionnaire items include the total
number of times the e-cigarette was used per day (i.e.
‘sessions’ not puffs), number of days using the e-
cigarette, strength of nicotine e-liquid used and fre-
quency of e-liquid purchased. Saliva samples collected at
baseline and two-month follow-up will be analysed for
cotinine, a measure of nicotine intake, arising from both
e-cigarette and tobacco use. We are measuring cotinine
to examine whether participants in the intervention
group cut down or replace their nicotine intake with e-
cigarette use.
We will also measure the number of people who tried
to stop smoking, uptake and use of the NHS SSS and
use of pharmacotherapy. Adverse event data will be re-
corded in the case report form (CRF) at 2- and 8-month
follow-ups and at other points if researchers are made
aware.
We will measure practitioner fidelity to the interven-
tion using a study-specific behaviour checklist, which
will be checked against audio recordings of the consulta-
tions after each session of annual review appointments.
The checklist will assess whether the GP or practice
nurse asked the participant about their smoking status,
whether they gave brief smoking management and cessa-
tion advice, whether they offered a referral and carried
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out the consultation according to the correct group
allocation (to assess contamination). We will draw on
conversation analytic (CA) methods to inform this
objective. Contamination will also be assessed in the
post-consultation questionnaire, where all participants
will be asked to report on whether e-cigarettes and
other smoking cessation aids were mentioned during
the consultation.
To measure acceptability of the intervention, we will
examine participants’ views about the care they have re-
ceived on their smoking in both arms by questionnaire
immediately after the consultation and through semi-
structured interviews with the intervention group only.
Participants will be asked to rate how helpful and appro-
priate they found practitioners’ advice and support on
smoking. They will also be asked about the quality of ad-
vice given via recall of key points of the consultation,
which will be triangulated with audio recordings of the
consultations. At 2 months, participants in the interven-
tion arm will be asked whether they used the study-
dedicated telephone support service, the practical sup-
port booklet and online video tutorials; they will rate
each resource on a five-point Likert scale from “Very
unhelpful” to “Very helpful”. We will assess attitudes to-
wards e-cigarettes, cutting down and stopping smoking
in a questionnaire administered at baseline and 2
months, as a measure of self-efficacy and outcome
expectations.
Before intervention training begins and after all thera-
peutic visits have been completed at a practice, practi-
tioners will be given a questionnaire about their
attitudes regarding e-cigarettes as a tool for smoking
cessation, as a measure of self-efficacy and outcome ex-
pectations. Practitioners and the vape team will be inter-
viewed about their experiences of the programme after




This is not a trial of an investigational medicinal prod-
uct. E-cigarettes are a consumer product and the devices
used in the trial are readily available to purchase in
stores and online. For the purposes of the trial, we will
record adverse events in the case report form by asking
the participant to complete a symptoms checklist at the
2-month follow-up appointment. The checklist will con-
tain symptoms commonly reported in previous studies
on e-cigarettes [39], including throat/mouth irritation,
cough, dry mouth, shortness of breath, headache, nau-
sea, dizziness, stomach pain and palpitations. Partici-
pants will rate whether they have been troubled by any
of these symptoms in the past 24 h, on a five-point
Likert scale from “Not at all” to “Extremely”.
In this population, we expect that serious adverse
events such as hospitalisation and death will occur dur-
ing the 8 months of observation. The Cochrane review
provides evidence that e-cigarettes do not cause serious
adverse events but the data are sparse and imprecise
[39]. As such, there are no expected serious related ad-
verse events in this study. However, to provide further
evidence on this, we will collect data on the occurrences
of serious adverse events at each follow-up. We will as-
sess each SAE in a blinded manner for relatedness to the
intervention by the chief investigator (CI) for monitoring
patient safety. For the purpose of trial reporting, how-
ever, we will convene an independent committee to
make this judgement. Reports of related and unexpected
SAEs (RUSAEs) will be reported to the REC within 15
working days of the chief investigator becoming aware
of the event.
Trial closure
The end of study is the date of the last debrief of the last
participant following the 8-month follow-up.
Statistics and analysis
Sample size
In order to correct the type 1 error rate for the fact that
there are two primary outcomes we will be using the
Holm-Bonferroni method of adjustment [59]. The
smaller P value will be compared to an alpha of 0.025
(this will probably be for reduction in smoking) and if
this is significant, the larger P value (which will probably
be for cessation) will be compared to an alpha of 0.05. A
total sample size of 320 will allow us to detect a risk ra-
tio of 2.8 for the proportion of patients reducing their
smoking and a risk ratio of 3.4 for the proportion of pa-
tients who stop smoking [38]. This assumes power of
90% and control group rates of 5% and 8% for stopping
and reducing, respectively [38]. No allowance will be
made for loss to follow up as all such cases will be as-
sumed to have continued their baseline level of smoking.
We expect to see adherence to the behavioural inter-
vention by practitioners of 70%, use of the e-cigarette at
follow-up of 40%, and follow-up 70% of enrolled partici-
pants. We will be able to estimate these proportions
with 95% confidence intervals being no greater than ±8%
with a sample of 160 people in the intervention group
and ±6% for the whole sample of 320 participants.
Analysis plan
Primary and secondary analyses
The proportion of participants who reduce smoking in
each group will be presented. A log-binomial regression
model will be applied to the data and the treatment ef-
fect will be reported as a relative risk and 95% confi-
dence interval, adjusted for GP practice. A similar
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procedure will be used to analyse the proportion of par-
ticipants who abstain from smoking. Analyses will be
carried out on an intention-to-treat basis, according to
the Russell Standard [60], where participants lost-to-
follow up are assumed to be smokers or not to have re-
duced and we will impute missing anabasine concentra-
tions with the baseline value.
The mean (SD) change in salivary anabasine from
baseline to 2 months will be reported for each group
and the difference and 95% CI will be computed using
linear regression with adjustment for GP practice. As-
sumptions of linear regression will be assessed and if vi-
olated a Mann-Whitney test will be adopted and the
median (IQR) will be used to summarise the data and
difference in medians (95% CI) will be reported.
Other analyses
For examining uptake and use of e-cigarettes, we will
calculate the proportion of participants who take up the
offer of an e-cigarette and the proportion who continue
to use them at 2- and 8-month follow-ups. Proportions
will be reported using descriptive statistics. Continued
use of e-cigarettes will mean either use until complete
smoking cessation was achieved or continued use on >
50% days between baseline and follow-up. For changes
in nicotine intake, we will calculate the mean change in
salivary cotinine concentrations from baseline to 2-
month follow-up for each group and the difference and
95% CI will be computed using linear regression with
adjustment for GP practice. Assumptions of linear re-
gression will be assessed and if violated a Mann-
Whitney test will be adopted and the median (IQR) will
be used to summarise the data and difference in medians
(95% CI) will be reported.
We will compare the proportion of people who con-
sent to enrolment into the study and complete 2- and 8-
month follow-ups. We will examine these outcomes sep-
arately at each recruitment centre to assess the general-
isability of our recruitment procedures. Proportions will
be reported using descriptive statistics and the difference
between trial arms and 95% CI will be calculated.
For participants’ views of the programme (assessed by
Likert scale questions), we will calculate the total score
and compare these by trial arm using linear regression
with adjustment for GP practice. Participants’ recall of
key points of the consultation (reported as a yes/no vari-
able) will be presented as frequencies and compared be-
tween the two arms using a chi-squared test.
Practitioner fidelity to the intervention will be
assessed using a rating scale for key elements in the
behavioural interventions and summarised as a score.
These are descriptive process data and relate only to
the intervention group.
The patient, practitioner and vape team interview ana-
lysis will follow the Framework approach [61], categoris-
ing data into cases and coded themes. We will follow an
inductive approach, drawing on participants’ perspec-
tives and experiences of the intervention to develop a
coding matrix. Interviews will be analysed as the data
are collected so that insights from initial data analysis
can be explored in later interviews and used to refine
themes and categories. We will carry out this process
until data saturation is reached, where no new themes
emerge. Data will be analysed using NVivo software.
We will analyse intervention delivery during the con-
sultations using conversation analysis (CA), a well-
established qualitative methodology used to analyse the
sequential organisation of verbal and non-verbal aspects
of talk-in-interaction [62]. CA has been extensively ap-
plied in routine healthcare, particularly in general prac-
tice settings [63], and is now beginning to be applied to
the analysis of talk-based healthcare interventions in
RCTs [64, 65]. The aim is to uncover differences in the
communication practices used by clinicians that seem
more or less effective at persuading participants to take
and try using e-cigarettes. We will transcribe and analyse
a sample of 50 audio-recordings using this technique,
firstly by identifying the consultations that resulted in
patients trying an e-cigarette and comparing communi-
cation practices and patient uptake across practitioners.
Most communication training uses instruction or role-
play but this often fails to give insight into the complex-
ity of real-life encounters. Real examples of ‘trainables’
from the CA analysis, highlighting ‘what works’, i.e. the
kind of interactional issues that can occur during inter-
vention delivery and the techniques that can best resolve
them, will be collected to inform future work. By doing
so we will be able to demonstrate both ‘plausible fram-
ings and efficacious implementations’ of our interven-
tion, and ways in which communication behaviour
change can be incorporated into an existing clinical skill-
set [66].
Data handling, record keeping and retention
The trial is being run as part of the portfolio of trials in
the Primary Care Clinical Trials Unit (PC-CTU) at the
University of Oxford. The data management will be run
in accordance with the Trials Unit standard operating
procedures (SOPs), which are fully compliant with Good
Clinical Practice (GCP). A study-specific Data Manage-
ment Plan (DMP) will be developed for the trial outlin-
ing in detail the procedures that will be put in place to
ensure that high quality data are produced for statistical
analysis.
A unique trial-specific number and/or code in any
database will identify the participants. All data will be
directly entered into electronic case report forms
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(eCRFs). A full pre-entry review and electronic data val-
idation for all data entered into the clinical database will
be provided by study-specific programmed checks. All
paper data will be locked in secure cabinets and only the
researchers will have access to the files. On all trial-
specific documents, other than the signed consent, the
participant will be referred to by the trial participant
number/code, not by name. A separate database will be
used to securely store all identifiable patient information
required to contact patients and permit follow up. Ac-
cess to this information will be strictly on a need to
know basis.
On completion of the trial and data cleaning, the study
documentation will be transferred to a secure, GCP-
compliant archiving facility, where they will be held for
5 years. Participants’ identifiable information will be
destroyed at the end of the trial. Prior to database lock,
the Data Manager and the Trial Statistician will under-
take a dataset review. Following this, quality control will
be performed on queries relating to critical data items
by the Data Manager.
Sample handling
Researchers will obtain saliva samples from participants
at baseline and 2-month follow-up visits to measure sal-
ivary cotinine and anabasine concentrations. Cotinine, a
major metabolite of nicotine, has a half-life of approxi-
mately 20 h in smokers [67] and is stable at room
temperature for up to 12 days [68]. Anabasine, a specific
biomarker of tobacco smoke, has a half-life of 16 h [69]
and is also stable at room temperature for up to 14 days.
Saliva will be collected in a plastic vial containing a
sterile dental roll (Salivette, Sarstedt). The container will
be labelled with the patient ID, type of sample, collection
date and time, then transported back to the university.
Samples will be sent to the laboratory as soon as they
are collected, or they may be stored for up to 7 days at
room temperature until they are shipped in batches to a
laboratory. The laboratory will store and freeze the sam-
ples at − 20 °C until there is a sufficient batch for pro-
cessing. Salivary cotinine and anabasine concentrations
will be determined by liquid chromatography-tandem
mass spectrometry (LC-MS/MS) assay. If insufficient sal-
iva is available in the sample for both cotinine and ana-
basine analysis, anabasine will take priority in the assay.
All samples will be disposed of by laboratory staff after
final analysis.
Quality assurance procedures
The trial will be conducted in accordance with the
current approved protocol, GCP, relevant regulations
and standard operating procedures.
Regular monitoring will be performed according to
GCP. Data will be evaluated for compliance with the
protocol and accuracy in relation to source documents.
Following written standard operating procedures, the
monitors will verify that the clinical trial is conducted
and data are generated, documented and reported in
compliance with the protocol, GCP and the applicable
regulatory requirements.
An independent Trial Steering Committee (TSC) will
provide oversight of all matters relating to participant
safety and data quality. The TSC will include at least
one independent clinician, an independent statistician
and a participant representative. The TSC will be asked
to review the trial protocol and will provide expert ad-
vice to the Trial Management Group on the trial
progress.
A data monitoring committee is not required for this
study as it is of low risk and the trial protocol will not
be modified based on interim data.
Patient and public involvement
The study is supported by a patient advisory group who
are involved in several aspects of the trial, including the
design, management and conduct of the trial through
membership of the trial steering committee. Members
include active smokers from our target population,
smokers trying to quit and ex-smokers, some of whom
have used or are currently using e-cigarettes. Addition-
ally, one member of the group is an experienced vaper
and will lead the telephone support service that will pro-
vide technical support to patients in the trial on e-
cigarette use. The group will help develop and review
the practical support booklet, online content and lay
summaries of the study findings.
Expenses and benefits
As there is no therapeutic benefit to participants for at-
tending the baseline and follow-up appointments in per-
son at 2 and 8 months, we will pay those participants
who attend a reimbursement (£30 voucher) to cover the
cost and inconvenience of attending. Patients who are
invited to take part in post-follow-up interviews will be
reimbursed £20. For participating in interviews, GPs will
be reimbursed £80 per hour, practice nurses will be re-
imbursed £21.96 per hour and members of the vape
team will receive £20 reimbursement.
Discussion
The heart of this intervention is a brief intervention
from the GP or practice nurse to patients to advise them
that using an e-cigarette is safer than continuing
to smoke and may help them cut down their smoking.
That their GP or practice nurse believes this to be true
would be effectively communicated by a consent proced-
ure that fully outlined the nature of both interventions;
however, this would break the trial randomisation.
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Instead, to reduce contamination, we will inform poten-
tial participants that this is a trial about the way practi-
tioners have conversations with people about their
smoking. This approach may also reassure people who
have no plans to stop smoking that joining the study will
not involve them being subject to hectoring to do some-
thing they do not want to do. We will ensure that all pa-
tients are fully debriefed and are informed about the
purpose of the study at the end of the trial with a
debriefing information sheet.
If practitioners can be trained to offer advice about e-
cigarettes and patients take up this offer, patients at high
risk of increased morbidity and mortality from smoking
could be helped to reduce their smoking and increase
their chances of quitting. For almost all these specified
smoking-related conditions, stopping smoking would be
the single most effective way to improve health for pa-
tients and is likely to reduce health service costs.
Trial status
Recruitment began in June 2018. At the time of
manuscript submission, the trial was still in the re-
cruitment phase, with 243 participants recruited as of
1st April 2019.
At the time of manuscript resubmission, recruitment
had finished in May 2019 and the trial was in follow-up.
This manuscript is based on version 3.0 (21 May 2019)
of the study protocol.
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with relevant regulations and with Good Clinical Practice.
Written versions of the participant information and informed consent forms
will be re-presented to participants at the baseline visit by the study re-
searcher, detailing no less than: the nature of the study; what it will involve
for the participant; the implications and constraints of the protocol; the
known side effects and any risks involved in taking part. It will be clearly
stated that the participant is free to withdraw from the study at any time for
any reason without prejudice to future care, without affecting their legal
rights, and with no obligation to give the reason for withdrawal.
The participant will be allowed as much time as wished to consider the
information, and the opportunity to question the Investigator, their GP or
other independent parties to decide whether they will participate in the
study. Written informed consent will then be obtained by means of
participant dated signature and dated signature of the person who
presented and obtained the informed consent. The person who
obtained the consent must be suitably qualified and experienced, and
have been authorised to do so by the chief investigator. A copy of the
signed informed consent will be given to the participant, a copy will be
retained at the study site and the original signed form will be stored
securely at the University of Oxford.
Verbal consent will be obtained for interviews conducted over the
telephone with practitioners and members of the vape team and recorded
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consent form will be sent to participants.
As the true nature of the study is disguised from participants, the
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true nature and scope of the study after they have completed their 8-
month follow up.
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